These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18851961)

  • 21. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV; Groenewegen HJ; Voorn P
    Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
    Jeon MY; Lee WY; Kang HY; Chung EJ
    Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
    Stockwell KA; Scheller D; Rose S; Jackson MJ; Tayarani-Binazir K; Iravani MM; Smith LA; Olanow CW; Jenner P
    Exp Neurol; 2009 Oct; 219(2):533-42. PubMed ID: 19619533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
    Kuno S
    Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
    Silverdale MA; Nicholson SL; Ravenscroft P; Crossman AR; Millan MJ; Brotchie JM
    Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
    Yarkov AV; Hanger D; Reploge M; Joyce JN
    Pharmacol Biochem Behav; 2003 Dec; 76(3-4):551-62. PubMed ID: 14643855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
    Tidey JW; Bergman J
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
    Samadi P; Grégoire L; Bédard PJ
    Neuropharmacology; 2003 Dec; 45(7):954-63. PubMed ID: 14573388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys.
    Rowlett JK; Platt DM; Yao WD; Spealman RD
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1135-43. PubMed ID: 17351103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M; Madras BK
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia.
    Lublin H
    Clin Neuropharmacol; 1995 Dec; 18(6):533-51. PubMed ID: 8681313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.
    Calon F; Morissette M; Ghribi O; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):127-38. PubMed ID: 11853103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.